A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
NCT01590641
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis B
HBV
Interventions
DRUG:
Single Ascending Dose (SAD) Cohorts GS-9620
DRUG:
Multiple Ascending Dose (MAD) Cohorts
Sponsor
Gilead Sciences